UNSPSC 51261505: Indoramin hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQ0Z3K8W92, chemically known as benzamide, n-(1-(2-(1h-indol-3-yl)ethyl)-4-piperidinyl)-, monohydrochloride but more generally known as indoramin hydrochloride, which bears US NIH Compound Identifier 38102. European Medicines Agency schedules Indoramin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02679MIG.

Most nations, for tariff and trade purposes, schedule indoramin hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, INDORAMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)NC2CCN(CC2)CCC3C[NH]C4C3CCCC4.CL.

UNSPSC 51261505 Indoramin hydrochloride is a Commodity code that nominally covers a single pharmaceutical product, but the recent state and local opportunities tagged under it show no alignment with indoramin procurement. Seminole County, Florida's IFB60459723LAS seeks naloxone and drug deactivation systems for community health delivery, and the Texas Health and Human Services Commission's RFI HHS0017013 requests vendor capabilities for a direct-to-manufacturer prescription program — neither solicitation involves indoramin hydrochloride. The mismatch suggests that either the code has been misapplied in tagging these opportunities or the code sees minimal relevant procurement activity in the state and local market. State and local issuing bodies pursuing pharmaceutical procurement span county health departments and state human services agencies, though the recent sample is too small to characterize issuing-body concentration or repeat-buyer patterns.

Activity in this code appears limited to two recent records: Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a response deadline of July 26, 2023 (a historical date that may reflect data-sourcing artifacts); and the Texas HHS Commission's April 2026 RFI for direct-to-manufacturer pharmacy capabilities with no stated response window or budget. Florida and Texas show the only recent state and local activity in the dataset, though neither represents procurement of the code's stated commodity. Vendors evaluating this code should verify whether state and local procurement offices have reassigned indoramin hydrochloride to a different UNSPSC designation or whether pharmaceutical procurement at the state and local level concentrates under broader family or class codes covering finished pharmaceuticals or pharmacy benefit management rather than active-ingredient commodities.